The short answer
The added bleeding risk from Ginkgo biloba with mefenamate is uncertain. Review the exact product, dose and your bleeding history with your prescriber.
What this answer covers
Oral Ginkgo biloba with oral mefenamic acid 250 mg capsules. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
- Supplement or preparation
- Ginkgo biloba
- Medication ingredient
- mefenamate
What the evidence shows
A short study in healthy men found no additional measured bleeding-time or platelet effect when a defined ginkgo extract was added to aspirin. This is useful counterevidence, but it did not test this NSAID or patients with a history of GI bleeding.
Consider this medicine’s own effects
This entry uses the oral mefenamic acid capsule label, explicitly linked to the mefenamate ingredient. It covers acute pain for no more than seven days and primary dysmenorrhea. Serious GI bleeding and ulcer warnings remain relevant even during a short course; evidence for another NSAID does not establish this supplement combination’s risk.
Review the exact product
The final European ginkgo monograph cautions about use with medicines affecting clotting, including other NSAIDs. Review the exact leaf extract and dose with your pharmacist. This precaution does not establish a measured increase in bleeding for every ginkgo product.
Know when to get help
oral mefenamic acid 250 mg capsules can cause serious GI bleeding even without a supplement. Seek urgent care for vomiting blood or black, tarry stools, and report persistent stomach pain or unusual bleeding. Tell your prescriber about other pain medicines, aspirin and anticoagulants. A few hours of separation has not been shown to prevent an added bleeding effect.
Evidence and practical considerations
Side effects & toxicity
An increased bleeding or GI-injury rate specifically from Ginkgo biloba with mefenamate has not been established.
- Exact scope
- Oral Ginkgo biloba with oral mefenamic acid 250 mg capsules. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable. with Exact mefenamate IN 257844 linked by current RxNorm to mefenamic acid PIN 6693. The inspected oral acid capsules supply the explicit ingredient bridge, not meclofenamate or a different fenamate.
- Medication form and route
- Oral
What remains uncertain
- Available supplement-only and other-drug studies do not establish exact-pair clinical harm or exclude rare events. No validated preventive spacing interval.
Factors that may matter: Exact preparation and dose; Fasting versus fed dosing; Bleeding and ulcer history; Other medicines.
Read the supporting source summaries
Source 1: Current prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Prescription oral oral mefenamic acid 250 mg capsules users; short human pharmacology studies where described.
Short-term acute pain up to seven days and primary dysmenorrhea indications. Serious GI warnings; magnesium hydroxide raises peak concentration and AUC in a small human study.
How this applies: Exact current product label. Exact mefenamate IN 257844 linked by current RxNorm to mefenamic acid PIN 6693. The inspected oral acid capsules supply the explicit ingredient bridge, not meclofenamate or a different fenamate.
Exact oral product label; no measured botanical co-use incidence. Ingredient, route, preparation and comparator differences must be retained.
Source 2: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 50 healthy men aged 20-44.
No added measured bleeding-time or platelet/coagulation effect.
How this applies: Indirect for oral mefenamic acid 250 mg capsules co-use; exact preparation and endpoint retained.
Abstract-only; aspirin is a different medicine and the short study does not exclude rare bleeding.
Source 3: Medication terminology
rxnav.nlm.nih.gov · Source check Sep 10, 2026
Population: Terminology.
mefenamate is IN. Exact mefenamate IN 257844 linked by current RxNorm to mefenamic acid PIN 6693. The inspected oral acid capsules supply the explicit ingredient bridge, not meclofenamate or a different fenamate.
How this applies: Exact identity.
Not clinical evidence.
Research assessment: · Open full citations ↗
Side effects & toxicity
Defined ginkgo preparations warrant review with NSAIDs under regulatory guidance.
- Exact scope
- Oral Ginkgo biloba with oral mefenamic acid 250 mg capsules. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable. with Exact mefenamate IN 257844 linked by current RxNorm to mefenamic acid PIN 6693. The inspected oral acid capsules supply the explicit ingredient bridge, not meclofenamate or a different fenamate.
- Medication form and route
- Oral
What remains uncertain
- Precaution based on defined supplement evidence and the individual drug label; no exact combination event rate or universal discontinuation rule.
Factors that may matter: Exact preparation and dose; Fasting versus fed dosing; Bleeding and ulcer history; Other medicines.
Read the supporting source summaries
Source 1: Current prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Prescription oral oral mefenamic acid 250 mg capsules users; short human pharmacology studies where described.
Short-term acute pain up to seven days and primary dysmenorrhea indications. Serious GI warnings; magnesium hydroxide raises peak concentration and AUC in a small human study.
How this applies: Exact current product label. Exact mefenamate IN 257844 linked by current RxNorm to mefenamic acid PIN 6693. The inspected oral acid capsules supply the explicit ingredient bridge, not meclofenamate or a different fenamate.
Exact oral product label; no measured botanical co-use incidence. Ingredient, route, preparation and comparator differences must be retained.
Source 2: Final regulatory herbal monograph
ema.europa.eu · Source check Sep 10, 2026
Population: Users of specified ginkgo leaf preparations.
Cautions that anticoagulant/antiplatelet effects, including those of other NSAIDs, may be influenced.
How this applies: NSAID class precaution with individual drug counterevidence retained.
Regulatory precaution, not exact oral mefenamic acid 250 mg capsules trial. Different extracts and populations may differ.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Sources checked and article drafted. | |
| Research summary published |
Article revision: 6893e3e19a0b0c14
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.